vida: extract claims from 2026-04-29-cms-mssp-py2024-2-4b-savings-vbc-structural-proof

- Source: inbox/queue/2026-04-29-cms-mssp-py2024-2-4b-savings-vbc-structural-proof.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

@@ -13,7 +13,7 @@ related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category
 supports: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients"]
 reweave_edges: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|supports|2026-04-14", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14"]
 sourced_from: ["inbox/archive/health/2026-04-13-kff-glp1-access-inversion-by-state-income.md"]
-related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence"]
+related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access"]
 ---
 
 # GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
@@ -39,3 +39,10 @@ The Medicare GLP-1 Bridge program demonstrates that access inversion operates at
 **Source:** KFF 2025 poll condition-specific usage
 
 Among patients with diagnosed conditions showing clear clinical benefit, uptake remains limited: 45% of diabetes patients and 29% of heart disease patients currently using GLP-1s. Even in populations with established medical indication and likely insurance coverage, majority non-uptake persists. The 56% affordability difficulty rate among current users demonstrates cost barriers operate even after initial access is achieved.
+
+
+## Extending Evidence
+
+**Source:** HR Brew December 2025, 9amHealth partnership announcements
+
+The utilization vs. coverage divergence is now quantified: GLP-1 usage among surveyed populations (likely employer benefits) has 'more than doubled since 2023, reaching 49%' while total covered lives declined 22% (3.6M → 2.8M). This creates a dual-track access system where those who maintain coverage show dramatically higher utilization, while total population-level access worsens. The 9amHealth No-Barriers Bundle integrates medications from both Eli Lilly and Novo Nordisk at fixed monthly costs, but is only in discussions with employer groups as of early 2026 with no disclosed enrollment.

domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-28-glp1-managed-access-operating-systems-payer-infr
 scope: structural
 sourcer: on/healthcare.tech
 challenges: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
-related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression"]
 ---
 
 # Manufacturer direct-to-employer GLP-1 channels launched 2026 represent structural challenge to PBM intermediation by offering 55-60 percent price compression while bypassing traditional pharmacy benefit architecture
@@ -39,3 +39,10 @@ But the structural challenge is real: if manufacturers can profitably deliver GL
 **Source:** PHTI December 2025 employer report
 
 Eli Lilly Employer Connect launched March 5, 2026 at $449/dose with partnerships across 15+ program administrators (GoodRx, Teladoc, Calibrate, Form Health, Waltz). Novo Nordisk launched parallel DTE with Waltz Health and 9amHealth on January 1, 2026. Both manufacturers are bundling behavioral support infrastructure into the DTE channel, not just offering price compression.
+
+
+## Supporting Evidence
+
+**Source:** HR Brew/PR Newswire Q4 2025-Q1 2026 DTE announcements
+
+Both major GLP-1 manufacturers (Eli Lilly via Employer Connect, Novo Nordisk via 9amHealth/Waltz Health partnerships) now operate DTE channels as of Q1 2026. Novo's Waltz Health DTE program launched January 1, 2026 for FDA-approved obesity medications. 9amHealth's No-Barriers Bundle integrates access to medications from both manufacturers at fixed monthly costs. However, neither manufacturer has disclosed enrollment data or market penetration, and expert consensus characterizes DTE as 'manufacturers positioning themselves as more active participants in employer access strategy' rather than structural displacement of PBM intermediation.

domains/health/mssp-acos-generate-record-savings-while-improving-quality-proving-cost-quality-cooptimization.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: "CMS MSSP 2024 results show ACOs outperformed non-ACO groups on depression screening (53.53% vs 44.42%), blood pressure control (71.21% vs 67.82%), and cancer screening while generating $2.48B net savings, defeating the under-treatment critique of value-based care"
+confidence: proven
+source: CMS Medicare Shared Savings Program 2024 Performance Year Results, September 2025
+created: 2026-04-29
+title: MSSP ACOs generated record $2.48B in net Medicare savings in 2024 for the eighth consecutive year while maintaining superior quality performance compared to non-ACO peers proving that cost and quality improvement are achievable simultaneously under value-based payment
+agent: vida
+sourced_from: health/2026-04-29-cms-mssp-py2024-2-4b-savings-vbc-structural-proof.md
+scope: structural
+sourcer: "Centers for Medicare & Medicaid Services"
+supports: ["the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness"]
+related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness"]
+---
+
+# MSSP ACOs generated record $2.48B in net Medicare savings in 2024 for the eighth consecutive year while maintaining superior quality performance compared to non-ACO peers proving that cost and quality improvement are achievable simultaneously under value-based payment
+
+The 2024 MSSP results provide the strongest empirical evidence that value-based care's structural fix thesis works at scale. ACOs generated $2.48B in net Medicare savings (after shared savings payments) for the eighth consecutive year, with per capita net savings increasing from $207 in 2023 to $241 in 2024. Critically, this cost reduction occurred alongside quality improvements across multiple clinical domains. ACOs outperformed non-ACO physician groups on Screening for Depression and Follow-up Plan (53.53% vs 44.42%), Controlling High Blood Pressure (71.21% vs 67.82%), and showed improved performance on A1c control and cancer screening. This simultaneous cost-quality improvement directly refutes the central critique of value-based care: that cost reduction incentives will lead to under-treatment. The data shows the opposite pattern—ACOs are both more cost-effective AND deliver higher quality care. The acceleration is also notable: per capita gross savings increased $128 year-over-year (from $515 to $643), the largest single-year jump in the program's history. Two-thirds of ACOs now participate in downside risk tracks (Level E or Enhanced), generating $5.4B of the $6.6B in gross savings, demonstrating that the transition to full risk-bearing is advancing despite aggregate payment statistics showing only 14% of total healthcare payments bearing full risk.

domains/health/mssp-downside-risk-adoption-accelerating-two-thirds-in-risk-tracks.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: "MSSP 2024 data shows 67% of ACOs in Level E or Enhanced tracks generating $5.4B of $6.6B gross savings, with CMS 2026 rules making two-sided risk the default, indicating structural acceleration of value-based care adoption"
+confidence: proven
+source: CMS Medicare Shared Savings Program 2024 Performance Year Results, September 2025
+created: 2026-04-29
+title: Two-thirds of MSSP ACOs now participate in downside risk tracks generating more than two-thirds of all savings demonstrating that the transition to full risk-bearing is accelerating despite slow aggregate payment statistics
+agent: vida
+sourced_from: health/2026-04-29-cms-mssp-py2024-2-4b-savings-vbc-structural-proof.md
+scope: structural
+sourcer: "Centers for Medicare & Medicaid Services"
+related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk"]
+---
+
+# Two-thirds of MSSP ACOs now participate in downside risk tracks generating more than two-thirds of all savings demonstrating that the transition to full risk-bearing is accelerating despite slow aggregate payment statistics
+
+The MSSP 2024 results reveal a critical structural shift in value-based care adoption that contradicts the narrative of stalled transition. Two-thirds of participating ACOs are now in Level E or Enhanced tracks—both of which include downside risk—and these risk-bearing ACOs generated $5.4B of the $6.6B in total gross savings (82% of all savings). This concentration of savings in risk-bearing arrangements demonstrates that full accountability drives superior performance. The transition is also accelerating institutionally: CMS 2026 rules make two-sided risk the default for new MSSP entrants and restrict one-sided participation, while simultaneously launching the Ambulatory Specialty Model (ASM) for heart failure and low back pain with mandatory risk-bearing. This policy direction directly contradicts the claim that value-based care adoption has stalled. The aggregate statistic showing only 14% of total healthcare payments bearing full risk reflects the SLOW PACE of transition across the entire healthcare system, not a failure of the model itself. Within MSSP—the largest federal value-based care program—the transition to risk-bearing is advancing rapidly, with two-thirds already participating and policy changes forcing the remainder to follow. The gap between MSSP's 67% risk-bearing rate and the healthcare system's 14% rate reveals that the bottleneck is adoption speed and policy will, not model viability.

domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md

@@ -363,3 +363,10 @@ Topics:
 **Source:** Papanicolas et al., JAMA Internal Medicine 2025, OECD Health at a Glance 2025
 
 Current US system shows treatable mortality gap of 95 vs OECD average 77 per 100,000 (confirming clinical system underperformance) and preventable mortality gap of 217 vs OECD average 145 (confirming the behavioral/social failure is larger). The spending-outcome decoupling within US states proves the current sick-care architecture cannot bend the curve even with higher spending, validating the need for structural transition to prevention-first systems.
+
+
+## Supporting Evidence
+
+**Source:** CMS MSSP 2024 Performance Year Results, September 2025
+
+MSSP ACOs in 2024 generated $2.48B in net savings while simultaneously outperforming non-ACO peers on depression screening (53.53% vs 44.42%), blood pressure control (71.21% vs 67.82%), and cancer screening. This empirically demonstrates the prevention-first flywheel in practice: aligned payment creates incentives that improve both cost and quality simultaneously, with per capita savings accelerating from $207 to $241 year-over-year.

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -1,29 +1,13 @@
 ---
-confidence: likely
-created: 2026-02-17
-description: VBC adoption shows a wide gap between participation and risk-bearing with 60 percent of payments in value arrangements but only 14 percent in full capitation revealing that most providers take
-  upside bonuses without accepting downside risk
-domain: health
-related:
-- federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings
-- home-based-care-could-capture-265-billion-in-medicare-spending-by-2025-through-hospital-at-home-remote-monitoring-and-post-acute-shift
-- GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months
-- Does prevention-first care reduce total healthcare costs or just redistribute them from acute to chronic spending?
-- attractor-molochian-exhaustion
-related_claims:
-- double-coverage-compression-simultaneous-medicaid-cuts-and-aptc-expiry-eliminate-coverage-for-under-400-fpl
-- medicaid-work-requirements-cause-coverage-loss-through-procedural-churn-not-employment-screening
-- upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure
-- medically-tailored-meals-achieve-pharmacotherapy-scale-bp-reduction-in-food-insecure-hypertensive-patients
-- hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022
-- uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant
-reweave_edges:
-- federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31
-- home-based-care-could-capture-265-billion-in-medicare-spending-by-2025-through-hospital-at-home-remote-monitoring-and-post-acute-shift|related|2026-03-31
-- GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04
-- Does prevention-first care reduce total healthcare costs or just redistribute them from acute to chronic spending?|related|2026-04-17
-source: HCP-LAN 2022-2025 measurement; IMO Health VBC Update June 2025; Grand View Research VBC market analysis; Larsson et al NEJM Catalyst 2022
 type: claim
+domain: health
+description: VBC adoption shows a wide gap between participation and risk-bearing with 60 percent of payments in value arrangements but only 14 percent in full capitation revealing that most providers take upside bonuses without accepting downside risk
+confidence: likely
+source: HCP-LAN 2022-2025 measurement; IMO Health VBC Update June 2025; Grand View Research VBC market analysis; Larsson et al NEJM Catalyst 2022
+created: 2026-02-17
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "home-based-care-could-capture-265-billion-in-medicare-spending-by-2025-through-hospital-at-home-remote-monitoring-and-post-acute-shift", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months", "Does prevention-first care reduce total healthcare costs or just redistribute them from acute to chronic spending?", "attractor-molochian-exhaustion", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk"]
+related_claims: ["double-coverage-compression-simultaneous-medicaid-cuts-and-aptc-expiry-eliminate-coverage-for-under-400-fpl", "medicaid-work-requirements-cause-coverage-loss-through-procedural-churn-not-employment-screening", "upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure", "medically-tailored-meals-achieve-pharmacotherapy-scale-bp-reduction-in-food-insecure-hypertensive-patients", "hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant"]
+reweave_edges: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31", "home-based-care-could-capture-265-billion-in-medicare-spending-by-2025-through-hospital-at-home-remote-monitoring-and-post-acute-shift|related|2026-03-31", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04", "Does prevention-first care reduce total healthcare costs or just redistribute them from acute to chronic spending?|related|2026-04-17"]
 ---
 
 # value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk
@@ -101,4 +85,10 @@ Relevant Notes:
 - [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] -- the 86% of payments not at full risk are systematically ignoring the factors that matter most for health outcomes
 
 Topics:
-- health and wellness
+- health and wellness
+
+## Extending Evidence
+
+**Source:** CMS MSSP 2024 Performance Year Results, September 2025
+
+MSSP 2024 results show that within the program, 67% of ACOs now participate in downside risk tracks (Level E or Enhanced), generating $5.4B of $6.6B in gross savings. This demonstrates that where policy enables full risk-bearing, adoption is advancing rapidly—the 14% aggregate statistic reflects slow system-wide transition, not model failure. CMS 2026 rules making two-sided risk the default for new MSSP entrants further accelerate this shift.

entities/health/waltz-health.md

@@ -0,0 +1,26 @@
+# Waltz Health
+
+**Type:** Healthcare access platform  
+**Domain:** GLP-1 direct-to-employer distribution  
+**Status:** Active (as of 2026-01)
+
+## Overview
+
+Waltz Health operates a direct-to-employer (DTE) access program for FDA-approved obesity medications, partnering with Novo Nordisk to bypass traditional PBM intermediation.
+
+## Timeline
+
+- **2026-01-01** — Launched DTE access program for FDA-approved obesity medications in partnership with Novo Nordisk
+
+## Business Model
+
+DTE channel for GLP-1 access, competing with traditional PBM distribution. No enrollment data or market penetration disclosed as of Q1 2026.
+
+## Market Position
+
+Part of the emerging manufacturer-direct distribution strategy alongside Eli Lilly's Employer Connect and 9amHealth's No-Barriers Bundle. Expert consensus characterizes DTE as 'incremental governance shift, not structural PBM displacement.'
+
+## Sources
+
+- HR Brew, December 2025
+- PR Newswire, January 2026

inbox/archive/health/2026-04-29-9amhealth-waltz-novo-dte-glp1-access-2026.md

@@ -7,10 +7,13 @@ date: 2025-12-19
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-29
 priority: medium
 tags: [GLP-1, direct-to-employer, Novo-Nordisk, 9amHealth, Waltz-Health, access, DTE, employer-benefits]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-29-cms-mssp-py2024-2-4b-savings-vbc-structural-proof.md

@@ -7,10 +7,13 @@ date: 2025-09-09
 domain: health
 secondary_domains: []
 format: report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-29
 priority: high
 tags: [value-based-care, ACO, MSSP, CMS, payment-reform, structural-fix, belief-3]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content